Home › Blastic Plasmacytoid Dendritic Cell Cancer › NCT05430971
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of BPDCN * Signed informed consent form for prospective patients Exclusion Criteria: \-
About the study
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.
Sponsor: Immune Oncology Research Institute · Participants: 200 · Started: Jul 1, 2022
Contact the study team
- Astghik Voskanyan, MD · Phone: +374 10 28 38 00
- Davit Melkonyan · Phone: +374 10 28 38 00
Official record on ClinicalTrials.gov — NCT05430971
Locations in the U.S.
| Florida | Sylvester Comprehensive Cancer Center, University of Miami, Miami Moffitt Cancer Center, Tampa |
| Washington | Seattle Children's Cancer and Blood Disorders Center, Seattle |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.